This article is more than 5 years old. Information may no longer be current.
NuVasive and AlloSource announce licensing agreement
NuVasive, Inc. and AlloSource, partners in the cellular allograft market for use in orthopedic surgical applications, announced that AlloSource has licensed from NuVasive certain intellectual property related to bone growth products containing endogenous mesenchymal stem cells.
The announcement, issued in a press release, noted the license and royalty agreement will enable AlloSource to distribute its recently introduced allograft cellular product, AlloStem. The agreement includes restrictions against AlloSource distributing into the spine market with a major partner other than NuVasive. AlloSource currently processes Osteocel Plus for NuVasive.
According to a joint statement issued by NuVasive and AlloSource,“This license agreement strengthens the relationship between our organizations and further validates the strength of the allograft stem cell intellectual property held by NuVasive. Our partnership in the distribution of Osteocel Plus, which is processed by AlloSource for NuVasive, has been very positive. We are collectively excited about the research being conducted by our companies to advance tissue processing techniques and we look forward to our continued leadership in this market.”